Quantcast

Latest Novartis Stories

2014-10-27 12:30:11

DUBLIN, Oct. 27, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global H1N1 Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A...

2014-10-27 08:29:37

bioCSL to take on expanded role in global influenza vaccine industry MELBOURNE, Australia, Oct. 27, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL. Combining bioCSL's existing influenza vaccine operations with the Novartis business will create the number two global player in the US$4 billion global...

2014-10-25 23:00:42

He will lead all research and development for the firm’s algae proteins used in human pharmaceuticals and specialty animal feed products. San Diego, CA (PRWEB) October 25, 2014 Triton Algae Innovations, a pioneer in synthetic biology, today announced Dr. Xun Wang has joined the firm as President and Director of all Research & Development. Triton has developed a patented synthetic biology platform for the production of high value algae-based proteins. According to Dr. Wang, the...

2014-10-21 08:28:24

Through music and resources Our Voice in Song(TM) inspires people living with relapsing MS to become more active managers of their disease EAST HANOVER, N.J., Oct. 21, 2014 /PRNewswire/ -- Today Novartis Pharmaceuticals Corporation launched a new multifaceted multiple sclerosis (MS) awareness campaign aimed to motivate people with relapsing MS to take charge of their disease. The campaign, Our Voice in Song(TM), features inspirational advocate and music artist David Osmond, who...

2014-10-20 16:27:09

- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 EAST HANOVER, N.J., Oct. 20, 2014 /PRNewswire/ -- Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) today voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment...

2014-10-20 08:31:57

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline. http://photos.prnewswire.com/prnvar/20111205/SF16052LOGO "We are pleased to welcome Dr. Londei to AnaptysBio's executive leadership team," said Hamza Suria,...

2014-10-16 00:20:40

BASEL, Switzerland, Oct. 16, 2014 /PRNewswire/ -- -- Integrated sales up 3 percent[1], with growth in all regions -- ELATUS(TM) orders exceed $200m in first nine months -- Full year integrated sales growth target of 6 percent maintained Group sales, including Lawn and Garden, increased by 2 percent at constant exchange rates in the third quarter of 2014. The increase in reported sales was also 2 percent. For the first nine months of 2014, sales rose by 3 percent at constant...

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST HANOVER, N.J., Oct. 15, 2014 /PRNewswire/ -- Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients...

2014-10-09 16:26:01

LONDON, Oct. 9, 2014 /PRNewswire/ -- The global market for seed treatment in cotton is forecast to maintain the slowest 2014-2020 CAGR of 5.3% in comparison to other crop types. With an estimated share of 46.7% in 2014, North America is the largest market for seed treatment in cotton applications, though Asia-Pacific is expected to register the fastest corresponding period CAGR of 7.3%.The market for seed treatment gains in significance due to a number of factors, prominent among...

2014-10-09 16:25:58

LONDON, Oct. 9, 2014 /PRNewswire/ -- The global market for seed treatment in rice is likely to post a relatively modest CAGR of 6.1% during the 2014-2020 analysis period. While North America is and would remain the largest market for seed treatment in rice, Asia-Pacific's demand is slated to exceed all other regions in terms of recording a CAGR of 8.5% between 2014 and 2020.The market for seed treatment gains in significance due to a number of factors, prominent among which are...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related